News & Events

UK Police Hosting Regional K-9 Certification and Trials


LEXINGTON, Ky., (July 8, 2016) — The University of Kentucky Police Department is hosting the United States Police Canine Association Region 5 Certification and Trials event beginning this Sunday July, 10, and continuing through Wednesday, July 13, at the Carnahan House in Lexington.
 
“Law enforcement canines serve an invaluable function both to their agencies and to the community they serve,” UKPD Chief Joe Monroe said. “We are honored to host the USPCA Region 5 Certification and Trials event this year.”
 
The United States Police Canine Association is the largest and oldest active organization of its kind. Region 5 encompasses law enforcement canine agencies across Kentucky, Ohio and Indiana. These canines will be seeking recertification in agility, obedience, tracking, criminal apprehension, article evidence, narcotics detection and explosives detection at the historic Carnahan House, located on UK's Coldstream Research Campus, just off Newtown Pike.
 
“Regional and national certification for canine law enforcement agencies are an important tool in standardizing the level of expertise these canines and their handlers must have to become credible witnesses in their respective fields,” said USPCA Region 5 President Jason Thomas.
 
In 2004, UKPD obtained its first canine as a result of a mutual aid agreement with the Bureau of Alcohol, Tobacco, Firearms and Explosives. The K-9 unit has grown to three canines — their names are Pink, Baska and Junior.
 
Members of the public are invited to attend the outdoor testing of law enforcement canines including the agility, obedience and criminal apprehension trials on Tuesday, July 12, and Wednesday, July 13.
 
For more information about USPCA, visit www.uspcaK9.com.
 
For more information about the Region 5 Certification and Trials, visit www.uky.edu/Police/.

Dr. Shepard-Jones Appointed Director of UK's Human Development Institute


LEXINGTON, Ky. (Feb. 25, 2016) —The University of Kentucky Office of the Vice President for Research has appointed Kathleen Sheppard-Jones as the new director of the Human Development Institute (HDI), a University Center for Excellence in Developmental Disabilities (UCEDD) at UK. 

Sheppard-Jones received her doctoral degree in educational psychology from UK in 2002 and has worked with HDI since 1996. She previously served as training director for the institute. In that role, she built relationships with faculty and staff across colleges at UK and beyond. In addition to her director responsibilities, Sheppard-Jones is also principal investigator across a variety of grants and contracts around quality supports for people through the lifespan. She is currently an adjunct professor in the Department of Early Childhood, Special Education and Rehabilitation Counseling.
 
”HDI promotes the inclusion, independence and contributions of people with disabilities across the lifespan," said Vice President for Research Lisa A. Cassis. "As one of 67 UCEDD programs across the nation, this mission is accomplished through research, education, information sharing, leadership and advocacy — across the Commonwealth and the nation. With 45 projects and over 200 staff, Dr. Sheppard-Jones’ background and experience building interdisciplinary collaboration will ensure HDI is part of the research agenda that improves life outcomes for all Kentuckians and particularly addresses disparities for those with disabilities.”
 
“I’m extremely honored to be HDI’s executive director," Sheppard-Jones said."We have huge challenges ahead of us, but I cannot imagine a better team of dedicated and innovative professionals, self-advocates and families with whom to share this journey. Together, we will forge ahead to promote a society that is inclusive for all, and help to erase health disparities for Kentuckians with disabilities. The University of Kentucky is an environment that will enable us to conduct state of the art translational research, provide training to interdisciplinary students who will be the leaders of tomorrow, and collaborate with communities to demonstrate service models that result in meaningful life outcomes.”

Lannett Company, Summit Biosciences Receives FDA Approval for Sumatriptan


LEXINGTON, Ky. (Feb. 22, 2016)  Lannett Company, Inc. announced today that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray, the therapeutic equivalent to the reference listed drug Imitrex® Nasal Spray, of GlaxoSmithKline. According to IMS, total U.S. sales in 2015 of Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray at Average Wholesale Price (AWP) were approximately $62 million. 
 

"We believe our Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray will be a first-to-market generic product," said Arthur Bedrosian, chief executive officer of Lannett. "Producing nasal delivery medications requires unique expertise and facilities that few possess. Our Sumatriptan Nasal Spray product was developed by Summit Biosciences Inc. and will be manufactured at its state-of-the-art facility located on the University of Kentucky's Coldstream Research Campus. We expect to commence marketing the product in the next several months."

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

About Summit Biosciences Inc.:
Summit Biosciences, founded in 2009, is a specialty pharmaceutical company focused on developing and commercializing generic and innovative nasal drug products. For more information, visit the company's website at www.summitbiosciences.com.

Craig Carter Named President of American Veterinary Epidemiology Society


Craig Carter

LEXINGTON, Ky. (Feb. 11, 2016) — Craig N. Carter, director and professor of epidemiology at the University of Kentucky Veterinary Diagnostic Laboratory (UKVDL), recently took the helm of the American Veterinary Epidemiology Society (AVES) as president for a five-year term. 
 
AVES was founded by James H. Steele in 1964 to recognize global leaders in infectious disease epidemiology and public health and to foster research to combat infectious diseases in both animals and humans. The society has recognized more than 70 world-renowned scientists through awarding the K.F. Meyer/James H. Steele Gold Headed Cane Award, which Carter received in 2011, primarily for his work on zoonotic diseases.
 
“I consider it such a great honor and privilege to serve as the president of the American Veterinary Epidemiology Society for the next five years," said Carter. "Since leaving my ambulatory practice in Texas, I have worked as an epidemiologist in service, research and teaching roles in the university, military and international consulting environments for over thirty years. Dr. Jim Steele — founder of the AVES and the CDC division of epidemiology — was my graduate professor, mentor and dear friend for many years until his death at 100 years young in 2013."
 
Carter was recruited from Texas A&M University to the UK College of Agriculture, Food, and Environment in 2005 to build an epidemiology program to provide for the early detection of animal disease outbreaks such as Mare Reproductive Loss Syndrome. In 2007, he was appointed to his current position at UKVDL where he oversees lab operations, conducts research and works with his graduate students.
 
One of Carter’s goals for the AVES is to attract more bright students into careers in epidemiology. Sponsored by Hartz Mountain Corporation, the AVES hosts its annual meeting each year as part of the American Veterinary Medical Association (AVMA) meeting.  The 2016 meeting will be held in July, in San Antonio, Texas. A celebration of the 100th anniversary of the U.S. Army Veterinary Corps will also be held at Fort Sam Houston in San Antonio in conjunction with the AVMA meeting. Carter’s military career spanned from 1967-2008, retiring as a full colonel in the U.S. Army Reserve Veterinary Corps. 
 
Carter said he has thoroughly enjoyed his many years as a faculty member at UK.
 
"Now nearing the end of my career, I delight in this opportunity to give something back to the AVES and to a scientific discipline that has been so good to me and the world.”

Piramal Pharma Solutions to invest $10M, add 40 jobs at Coldstream Laboratories


LEXINGTON, Ky. (Feb. 3, 2016) — Coldstream Laboratories, a pharmaceutical manufacturer now owned by Piramal Pharma Solutions, is planning a $10 million expansion that will add 40 jobs at their Coldstream Research Campus location in Lexington, KY.
 
Piramal Pharma Solutions plans to invest up to $10 million to expand operations at Lexington’s Coldstream Laboratories Inc., creating 40 new jobs, Gov. Matt Bevin and Lexington Mayor Jim Gray announced today. The India-owned company last year purchased Coldstream Labs, which develops and manufactures injectable pharmaceuticals.
 
“Growth in private-sector employment—particularly high-paying, skilled jobs like these—moves Kentucky forward on the national and global level,” Bevin said. “On behalf of all Kentuckians, I congratulate and thank Piramal Pharma Solutions and Coldstream for this investment to further strengthen Kentucky’s pharmaceutical industry. We are excited by this opportunity to become an increasingly important part of Piramal’s global footprint and look forward to many years of partnership with them.”
 
Coldstream Labs started in 1991 as the Center for Pharmaceutical Science & Technology, a unit of the University of Kentucky College of Pharmacy. It completed more than 200 development projects that led to clinical trials. In 2007, the college spun off Coldstream Labs as a private company owned by the University of Kentucky Research Foundation.
 
As a separate independent business, Coldstream Labs gained the ability and technical expertise to manufacture liquid and freeze-dried injectable products. In January 2015, the Research Foundation sold Coldstream Labs to Piramal Pharma Solutions., a global leader in pharmaceutical contract services, and the flagship division of the Mumbai, India-based Piramal Group. Under Piramal, Coldstream Labs can access the financial resources needed to expand its facilities and meet its customers’ needs.
 
“The excellence of the University of Kentucky Pharmacy program and the brainpower it has brought to Lexington are creating good jobs for our citizens,” Gray said. “These are homegrown jobs that build on our growing reputation in the pharmaceutical industry.”
 
The Piramal Group operates in more than 30 countries with a presence in 100-plus markets around the world. Piramal Pharma Solutions, a division of Piramal’s flagship company Piramal Enterprises Limited, also maintains U.S. operations in Bethlehem, Pa. in addition to Coldstream Labs.
 
To encourage the investment and job growth in Lexington, the Kentucky Economic Development Finance Authority (KEDFA) preliminarily approved the company for tax incentives up to $800,000 through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the agreement term through corporate income tax credits and wage assessments by meeting job and investment targets.
 
Additionally, KEDFA gave Coldstream Labs preliminary approval for up to $140,000 in tax incentives through the Kentucky Enterprise Initiative Act (KEIA). KEIA allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing.
 
Coldstream Labs can receive resources from the Kentucky Skills Network. Through the Kentucky Skills Network, companies are eligible to receive no-cost recruitment and job placement services, reduced-cost customized training and job training incentives. Last year, the Kentucky Skills Network trained more than 84,000 employees from more than 5,600 Kentucky companies.

Proposed Water Tank on Legacy Trail to Include Restrooms, Tees, Bike Racks


LEXINGTON, Ky. (Dec. 17, 2015) — The city of Lexington plans to spend $1.75 million to build restrooms and add trees and other amenities around a 70-foot-tall water storage tank to be built on the popular Legacy Trail on the Coldstream Research Campus by the end of December 2016.

 

The Fayette Urban-County Council recently approved the revamped plans for the new rest area. The tank — to be five stories tall and 200 feet in diameter — must be operational by the end of 2016.

 

As part of a $590 million overhaul of the city’s sanitary-sewer and storm-sewer systems, the city must install a “wet weather” storage tank near the Cane Run pump station. That pump station is at the back of the Coldstream Research Campus, off Newtown Pike on the Legacy Trail. The tanks are used to store water during heavy rain, helping to decrease the number of storm water overflows.

 

Charlie Martin, the city’s director of water quality, appeared before the council in September with a preliminary design. The designs unveiled Tuesday were altered slightly but contain the same design elements — a rest room, shade trees, bike racks, a water fountain and other amenities. The Legacy Trail currently has little shade and no restrooms.

 

Martin has met with stakeholders — including tenants of the Coldstream Research Campus, the Blue Grass Community Foundation, the Lexington Art League and others — for nearly a year to discuss ideas to make the are around the tank a rest area and not an eyesore.

November 2015 StreamLines Newsletter


The November 2015 StreamLines Newsletter can be found online here

In this issue:

 

Learn more about quick lunch options on the Coldstream Research Campus

  • Selma’s Catering
  • Paddock Grille at Embassy Suites
  • Food Trucks

UK's Coldstream Research Campus is Thriving


Over the years, skeptics have at times been publicly critical of what they perceived as a lack of activity on the University of Kentucky's Coldstream Research Campus. These days, there is plenty going on at Coldstream.
 
Carl Nathe of UK Public Relations and Marketing recently sat down with the executive director of Coldstream, George Ward, for a conversation on 'UK at the Half,' a feature about people and programs at the university, which airs at halftime of every live radio broadcast of Wildcat football and basketball on the UK Sports Network.
                                                   
To listen to the show, visit: ukath-2015-16-7_mixdown.mp3

Coldstream Research Campus Hosted Earth Day Cleanup


LEXINGTON, Ky. (May 6, 2015)  In support of Earth Day and the national Keep America Beautiful campaign, the University of Kentucky Coldstream Research Campus and the Lexington-Fayette Urban County Government's Parks and Recreation Department held a cleanup of the banks of the Cane Run Creek south of Citation Boulevard, near the bridge in front of Eastern State Hospital.

 

Due to recent rains, high water had deposited a great deal of litter along the banks of the creek.  A successful clean up effort led by Coldstream Research Campus staff members Jim Conner and Steve Johns took place on April 22, 2015. Organizers worked with friends from HP, Tempur Sealy and other Coldstream volunteers to pick up and sort trash and recyclables that was later removed by LFUCG.

 


 

UK sells interest in Coldstream Laboratories to major pharmaceutical company


Update: this transaction has been completed.

Piramal would locate major pharmaceutical operations in Lexington at Coldstream Research Campus


 
LEXINGTON, KY. (Jan. 15, 2015) -- The University of Kentucky is considering a $30.65 million offer for Coldstream Laboratories Inc. (CLI) and its high-tech facility located at Coldstream Research Campus.
 
A decision about whether to sell CLI will be made Thursday during meetings of the UK Research Foundation and the executive committee of the university's Board of Trustees.
On the table is an offer from Piramal Enterprises Limited, one of the 50 largest companies in India, with annual revenues exceeding $750 million and expertise in contract manufacturing of pharmaceuticals. 
 
"This development is an exciting one for UK, Coldstream Research Campus and our community as we continue efforts to commercialize the technology and intellectual property developed by the university at the research park," said Lisa Cassis, UK's interim vice president for research.
 
Incorporated in 2007, CLI is a specialty pharmaceutical contract manufacturer with an emphasis on clinical trial to commercial scale sterile manufacturing of liquid and lyophilized parenterals and injectables.
 
UK's Research Foundation, as the largest shareholder in CLI, was to consider a $25 million offer from Piramal Enterprises Limited  for the company's stock. The UK Board's Executive Committee, acting on behalf of the university's Board of Trustees, was to consider a $5.65 million offer for the CLI facility on the research park campus.
 
CLI has had considerable success in recent years including:
--A five-year National Cancer Institute contract in 2013, 
--Successful completion of Food and Drug Administration pre-approval inspections in 2014 for the production of pharmaceuticals. 
 
However, taking the next step in growing and commercializing its operations will require more capital infusion on a consistent basis going forward. As a result, university officials said, private ownership and investment offers the greatest potential for CLI's long-term future.
 
"UK realizes that while CLI has been increasingly successful in commercializing research and products developed at this facility, its long-term success will be bolstered by further investment, management and marketing expertise, and expanded product lines and capacity that can best be provided by a commercial owner," said Eric N. Monday, UK's executive vice president for finance and administration. 
 
To that end, Piramal would locate its North American Pharma Solutions Formulations headquarters in Lexington at the Coldstream Research Campus while also exploring the potential for partnerships with the UK College of Pharmacy, which is currently fifth-ranked nationally.
 
CLI currently has 97 employees with an average annual salary of $58,000. Piramal has expressed an interest in negotiating with current management to continue operating the business and officials have stated that they hope to expand the employee base and presence on the Coldstream campus.
 
"That interest on the part of a major player in this industry speaks well of our stewardship of this company as well as the management and employees who have developed CLI to this point," Monday said. "The potential for this company -- and commercialized research created by the College of Pharmacy -- is tremendous."
 
Syndicate content